huCART19

BIOLOGICAL3 trials

Sponsors

University of Pennsylvania, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaDiffuse Large Cell LymphomaEnd Stage Renal Failure on DialysisKidney FailureKidney Transplant

Phase 1

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

CompletedNCT02374333

University of PennsylvaniaAcute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma

Start: 2014-03-25End: 2021-09-02Updated: 2021-09-23

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

RecruitingNCT06056102

National Institute of Allergy and Infectious Diseases (NIAID)End Stage Renal Failure on Dialysis, Kidney Failure, Kidney Transplant

Start: 2024-05-09End: 2042-12-15Target: 20Updated: 2026-05-22

Phase 2

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

CompletedNCT03792633

University of PennsylvaniaAcute Lymphoblastic Leukemia

Start: 2019-01-18End: 2024-04-04Updated: 2025-06-05

Related Papers

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia

Blood2025-11-03

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Blood2024-11-051 citations

Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

Cell Reports Medicine2023-12-0120 citations

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma

Journal for ImmunoTherapy of Cancer2023-05-0119 citations

Impact of socioeconomic status on survival after CD19 CART therapy.

Journal of Clinical Oncology2022-06-01

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2021-11-0518 citations

Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL

Blood2021-11-053 citations

CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2020-05-2018 citations

Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019

Blood2019-11-133 citations

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2017-05-2094 citations

Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).

Journal of Clinical Oncology2017-05-2017 citations

Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.

Journal of Clinical Oncology2016-05-2024 citations